Across TCGA pan-cancer cohorts, TUBB2B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TUBB2B data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher TUBB2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TUBB2B expression acts as an unfavorable survival marker.
BRCA, SARC, and SKCM are the cancer types where TUBB2B Mutation most reproducibly stratifies survival.